Blood Test Aids Early Detection of Rheumatoid Arthritis
|
By LabMedica International staff writers Posted on 09 Mar 2015 |
|
Image: Severe rheumatoid arthritis in a hand which was never treated (Photo courtesy of James Heilman, MD).
A blood test that measures the levels of a certain protein can be used in conjunction with clinical assessments to assist with the diagnosis of rheumatoid arthritis is now available in North America.
Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder that primarily affects joints and it may result in deformed and painful joints, which can lead to loss of function. The disease may also have signs and symptoms in organs other than joints.
The JOINTstat test (Augurex Life Science; Vancouver, BC, Canada) measures 14-3-3η (eta), a protein involved in joint damage that leads to debilitation in patients with RA, a disease that affects one out of every 100 Canadians. High levels of 14-3-3η protein indicate that the patient should be referred to a rheumatologist. JOINTstat has been evaluated in clinical studies in over 3,000 patients and has been available in the USA since late 2013.
Extracellular 14-3-3η protein is a potent ligand and activator of intracellular signaling pathways that lead to the upregulation of inflammation and joint damage factors involved in RA pathogenesis. A quantitative enzyme-linked immunosorbent assay is used to assess 14-3-3η protein levels. Studies have shown that when the test is positive, greater than 0.19 ng/mL, it provides a 5 to 50 times greater likelihood of having RA versus non-RA. At high levels of greater than 80 ng/mL is an indicator of RA that will lead to more joint damage over three years and at lower levels of less than 0.4 ng/mL or negative in RA diagnosed patients indicates a higher likelihood of response to RA therapy.
Walter Maksymowych, MD, FRCPC, a professor in the department of medicine, division of rheumatology at the University of Alberta (Edmonton, AB, Canada) said, “When diagnosed early, rheumatoid arthritis can be better managed with drug therapies, resulting in better outcomes by limiting disease progression. Current diagnostic tests are limited in their ability to catch the disease early. With the availability of JOINTstat in Canada, physicians now have the opportunity to treat rheumatoid arthritis early, prior to the onset of significant joint damage. This represents an important milestone towards the goal of personalized medicine.” The study was presented at the Canadian Rheumatology Association (CRA) Annual Scientific Meeting held February 4–7, 2015, in Québec City (QC, Canada).
Related Links:
Augurex Life Science
University of Alberta
.jpg)
Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder that primarily affects joints and it may result in deformed and painful joints, which can lead to loss of function. The disease may also have signs and symptoms in organs other than joints.
The JOINTstat test (Augurex Life Science; Vancouver, BC, Canada) measures 14-3-3η (eta), a protein involved in joint damage that leads to debilitation in patients with RA, a disease that affects one out of every 100 Canadians. High levels of 14-3-3η protein indicate that the patient should be referred to a rheumatologist. JOINTstat has been evaluated in clinical studies in over 3,000 patients and has been available in the USA since late 2013.
Extracellular 14-3-3η protein is a potent ligand and activator of intracellular signaling pathways that lead to the upregulation of inflammation and joint damage factors involved in RA pathogenesis. A quantitative enzyme-linked immunosorbent assay is used to assess 14-3-3η protein levels. Studies have shown that when the test is positive, greater than 0.19 ng/mL, it provides a 5 to 50 times greater likelihood of having RA versus non-RA. At high levels of greater than 80 ng/mL is an indicator of RA that will lead to more joint damage over three years and at lower levels of less than 0.4 ng/mL or negative in RA diagnosed patients indicates a higher likelihood of response to RA therapy.
Walter Maksymowych, MD, FRCPC, a professor in the department of medicine, division of rheumatology at the University of Alberta (Edmonton, AB, Canada) said, “When diagnosed early, rheumatoid arthritis can be better managed with drug therapies, resulting in better outcomes by limiting disease progression. Current diagnostic tests are limited in their ability to catch the disease early. With the availability of JOINTstat in Canada, physicians now have the opportunity to treat rheumatoid arthritis early, prior to the onset of significant joint damage. This represents an important milestone towards the goal of personalized medicine.” The study was presented at the Canadian Rheumatology Association (CRA) Annual Scientific Meeting held February 4–7, 2015, in Québec City (QC, Canada).
Related Links:
Augurex Life Science
University of Alberta
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Rapid Sepsis Test
SeptiCyte RAPID
New
Repetitive Pipette
VWR® Stepper Pro
Latest Immunology News
- Study Finds Influenza Often Undiagnosed in Winter Deaths
- Combined Screening Approach Identifies Early Leprosy Cases
- Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
- FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
- Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
- Microfluidic Chip Detects Cancer Recurrence from Immune Response Signals
- Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
- Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
- New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
- Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
- Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
- Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
- Blood Test Could Identify Colon Cancer Patients to Benefit from NSAIDs
- Blood Test Could Detect Adverse Immunotherapy Effects
- Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy
- New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
Channels
Clinical Chemistry
view channel
Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms
Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more
Study Finds ApoB Testing More Effective Than LDL for Guiding Lipid Therapy
Routine blood tests that measure low-density lipoprotein (LDL), commonly known as “bad” cholesterol, are widely used to guide lipid-lowering therapy, but they do not always provide a complete picture of... Read more
AI-Enabled POC Test Quantifies Multiple Cardiac Biomarkers
Cardiovascular diseases are a leading cause of death, responsible for nearly 20 million deaths each year. Timely triage of myocardial infarction and heart failure hinges on rapid cardiac biomarker measurement,... Read more
Next Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read moreMolecular Diagnostics
view channel
Urine-Based Assay Predicts Severe Dengue Risk Early
Dengue is among the most widespread mosquito-borne infections, yet early risk stratification can be difficult when symptoms overlap with other febrile illnesses. Only about 2% to 5% of patients develop... Read more
CE-Marked Blood Test Enables Monitoring of Neuroinflammation in Multiple Sclerosis
Multiple sclerosis affects more than 2.9 million people worldwide and requires ongoing evaluation of disease activity to guide care. Routine monitoring often depends on magnetic resonance imaging (MRI),... Read more
Ultrasensitive Assay Tracks Resistance Mutations MRD Monitoring
Ultrasensitive circulating tumor DNA assessment is being applied to predict and track response to immunotherapy and to detect relapse across multiple solid tumors. Monitoring resistance mutations such... Read more
Extracellular Vesicle RNA Biomarkers Enable Noninvasive IBD Diagnosis and Monitoring
Inflammatory bowel disease (IBD) is a chronic, relapsing gastrointestinal condition whose incidence is rising in industrialized and newly industrialized countries, with prevalence in early‑industrialized... Read moreHematology
view channel
Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
Anemia detected in routine care can signal underlying pathology and is frequently encountered in adults. Because it is defined by hemoglobin levels below the normal range, it is often evaluated with red... Read more
Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
Chronic myelomonocytic leukemia (CMML) is a rare blood cancer in which acquired genetic mutations in bone marrow stem cells drive disease. Stem cell transplantation is the only curative option but carries... Read more
Microbiology
view channel
Syndromic Panel Enables Rapid Identification of Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance determinants to guide therapy, yet laboratories often face pressure to deliver clinically relevant results quickly... Read more
RNA-Based Workflow Identifies Active Skin Microbes for Dermatology Research
Human skin carries diverse microbial communities that influence barrier function and inflammation, yet identifying which organisms are metabolically active has been challenging. DNA-based surveys catalog... Read more
Cost-Effective Sampling and Sequencing Workflow Identifies ICU Infection Hotspots
Intensive care units face persistent threats from hospital-acquired infections, increasingly driven by drug-resistant bacteria. Rapidly pinpointing environmental reservoirs and transmission hotspots remains... Read more
Pathology
view channel
Biomarker Predicts Immunotherapy Response and Prognosis in Colorectal Cancer
Colorectal cancer is common and often lethal, and therapeutic decision-making is complicated by heterogeneous tumor microenvironments. Immunotherapy benefits only a small subset of patients, around 5%,... Read more
AI Improves Completeness of Complex Cancer Pathology Reports
Oncology teams increasingly rely on pathology reports that integrate histopathology, immunohistochemistry, and rapidly expanding biomarker testing. As patients live longer and undergo repeated analyses... Read more
AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more_image.png "Image: Through neoadjuvant therapy combining chemotherapy with immune checkpoint inhibitors (ICI) for 46 LAGC patients and single-cell transcriptome sequencing, researchers found that tumor cells in the treatment-sensitive group specifically upregulated MHC-II (tumor-specific major histocompatibility complex class II, tsMHC-II) molecules (photo courtesy of Science China Press)")
Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality worldwide, with China bearing nearly half of the global burden. Only a subset of patients benefit from... Read moreTechnology
view channel
Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read more
Noninvasive Sputum Test Detects Early Lung Cancer
Early detection remains critical for improving outcomes in lung cancer, yet clinicians increasingly encounter indeterminate pulmonary nodules found incidentally or through screening, complicating decision-making.... Read more
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
Beckman Coulter Gains CE Mark for Rapid Assay Distinguishing Bacterial vs Viral Infections
Clinicians often struggle to distinguish bacterial from viral infections at first presentation because symptoms overlap and definitive culture or molecular results can take hours or days.... Read more
